Recent advances targeting innate immunity-mediated therapies against HIV-1 infection

Microbiology and Immunology

Volumn 56, Issue 8, 2012, Pages 497-505

  Shankar, Esaki Muthu ^a   Velu, Vijayakumar ^b   Vignesh, Ramachandran ^c   Vijayaraghavalu, Sivakumar ^d   Rukumani, Devi Velayuthan ^a   Sabet, Negar Shafiei ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b EMORY UNIVERSITY   (United States)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein B mRNA editing, enzyme catalytic, polypeptide like 3G; HIV 1; SAM histidine aspartic acid (HD) domain containing protein 1; Therapies

Indexed keywords

ALISPORIVIR; ALPHA DEFENSIN; ALPHA INTERFERON; ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BETA CHEMOKINE; BETA DEFENSIN; BETA INTERFERON; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHLOROQUINE; CYCLOSPORIN A; DEFENSIN; HYDROXYUREA; INTERLEUKIN 28A; INTERLEUKIN 29; JANUS KINASE; KYNURENIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYCOPHENOLIC ACID; PEGINTERFERON; PENTOXIFYLLINE; PROTEGRIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; THALIDOMIDE; THYMOPENTIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; DENDRITIC CELL; DOWN REGULATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; JAK STAT SIGNALING PATHWAY; MACROPHAGE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TH17 CELL; UPREGULATION; VIRAL CLEARANCE; VIRUS REPLICATION;

HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864349783     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2012.00485.x     Document Type: Article

References (104)

1. Ellegård R., Shankar E.M., Larsson M. (2011) Targeting HIV-1 innate immune responses therapeutically. Curr Opin HIV AIDS. 6: 435-43.
2. Pulendran B., Ahmed R. (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-63.
3. Medzhitov R. (2007) Recognition of microorganisms and activation of the immune response. Nature 449: 819-26.
4. Iwasaki A., Medzhitov R. (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-95.
5. Cole A.M., Cole A.L. (2008) Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 59: 27-34.
6. Iqbal S.M., Kaul R. (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59: 44-54.
7. Cole A.M. (2006) Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 306: 199-230.
8. Moreau T., Baranger K., Dade S., Dallet-Choisy S., Guyot N., Zani M.-L. (2008) Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90: 284-95.
9. Ghosh M., Shen Z., Schaefer T.M., Fahey J.V., Gupta P., Wira C.R. (2009) CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Reprod Immunol 62: 60-71.
10. Garzino-Demo A. (2007) Chemokines and defensins as HIV suppressive factors: an evolving story. Curr Pharm Des 13: 163-72.
11. Pontillo A., Oshiro T.M., Girardelli M., Kamada A.J., Crovella S., Duarte A.J. (2012) Polymorphisms in inflammasome' genes and susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr 59: 121-5.
12. Levinson P., Kaul R., Kimani J., Ngugi E., Moses S., Macdonald K.S., Broliden K., Hirbod T. (2009) Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 23: 309-17.
13. Klotman M.E., Rapista A., Teleshova N., Micsenyi A., Jarvis G.A., Lu W., Porter E., Chang T.L. (2008) Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 180: 6176-85.
14. Zaragoza M.M., Sankaran-Walters S., Canfield D.R., Hung J.K., Martinez E., Ouellette A.J., Dandekar S. (2011) Persistence of gut mucosal innate immune defenses by enteric alpha-defensin expression in the simian immunodeficiency virus model of AIDS. J Immunol 186: 1589-97.
15. Furci L., Sironi F., Tolazzi M., Vassena L., Lusso P. (2007) Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 109: 2928-35.
16. Chang T.L., Vargas J., Jr., Delportillo A., Klotman M.E. (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115: 765-73.
17. Penberthy W.T., Chari S., Cole A.L., Cole A.M. (2011) Retrocyclins and their activity against HIV-1. Cell Mol Life Sci 68: 2231-42.
18. Gallo S.A., Wang W., Rawat S.S., Jung G., Waring A.J., Cole A.M., Lu H., Yan X., Daly N.L., Craik D.J., Jiang S., Lehrer R.I., Blumenthal R. (2006) Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 281: 18787-92.
19. Venkataraman N., Cole A.L., Ruchala P., Waring A.J., Lehrer R.I., Stuchlik O., Pohl J., Cole A.M. (2009) Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 7: e95.
20. Wang W., Cole A.M., Hong T., Waring A.J., Lehrer R.I. (2003) Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 170: 4708-16.
21. Cole A.M., Hong T., Boo L.M., Nguyen T., Zhao C., Bristol G., Zack J.A., Waring A.J., Yang O.O., Lehrer R.I. (2002) Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 99: 1813-8.
22. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., Springer T.A. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382: 829-33.
23. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., Moser B. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382: 833-5.
24. Amara A., Gall S.L., Schwartz O., Salamero J., Montes M., Loetscher P., Baggiolini M., Virelizier J.L., Arenzana-Seisdedos F. (1997) HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186: 139-46.
25. Xiang J., George S.L., Wunschmann S., Chang Q., Klinzman D., Stapleton J.T. (2004) Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363: 2040-6.
26. Roeske-Nielsen A., Fredman P., Mansson J.E., Bendtzen K., Buschard K. (2004) Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 91: 205-11.
27. Sweeney E.A., Lortat-Jacob H., Priestley G.V., Nakamoto B., Papayannopoulou T. (2002) Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 99: 44-51.
28. Jennes W., Sawadogo S., Koblavi-Deme S., Vuylsteke B., Maurice C., Roels T.H., Chorba T., Nkengasong J.N., Kestens L. (2002) Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 18: 171-7.
29. Tedla N., Palladinetti P., Kelly M., Kumar R.K., Digirolamo N., Chattophadhay U., Cooke B., Truskett P., Dwyer J., Wakefield D., Lloyd A. (1996) Chemokines and T lymphocyte recruitment to lymph nodes in HIV infection. Am J Pathol 148: 1367-73.
30. Trumpfheller C., Tenner-Racz K., Racz P., Fleischer B., Frosch S. (1998) Expression of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES genes in lymph nodes from HIV+ individuals: correlation with a Th1-type cytokine response. Clin Exp Immunol 112: 92-9.
31. Winkler C., Modi W., Smith M.W., Nelson G.W., Wu X., Carrington M., Dean M., Honjo T., Tashiro K., Yabe D., Buchbinder S., Vittinghoff E., Goedert J.J., O'brien T.R., Jacobson L.P., Detels R., Donfield S., Willoughby A., Gomperts E., Vlahov D., Phair J., O'brien S.J. (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279: 389-93.
32. Van Rij R.P., Broersen S., Goudsmit J., Coutinho R.A., Schuitemaker H. (1998) The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 12: 85-90.
33. Mummidi S., Ahuja S.S., Gonzalez E., Anderson S.A., Santiago E.N., Stephan K.T., Craig F.E., O'connell P., Tryon V., Clark R.A., Dolan M.J., Ahuja S.K. (1998) Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 4: 786-93.
34. Villalba S., Salvucci O., Aoki Y., De La Luz Sierra M., Gupta G., Davis D., Wyvill K., Little R., Yarchoan R., Tosato G. (2003) Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol 74: 880-8.
35. Berlier W., Cremel M., Hamzeh H., Levy R., Lucht F., Bourlet T., Pozzetto B., Delezay O. (2006) Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 21: 1135-42.
36. Cocchi F., Devico A.L., Lu W., Popovic M., Latinovic O., Sajadi M.M., Redfield R.R., Lafferty M.K., Galli M., Garzino-Demo A., Gallo R.C. (2012) Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases. Proc Natl Acad Sci USA 109: 5411-6.
37. Pagliaccetti N.E., Robek M.D. (2010) Interferon-λ in HCV infection and therapy. Viruses 2: 1589-602.
38. Ank N., Iversen M.B., Bartholdy C., Staeheli P., Hartmann R., Jensen U.B., Dagnaes-Hansen F., Thomsen A.R., Chen Z., Haugen H., Klucher K., Paludan S.R. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-85.
39. Liu M.Q., Zhou D.J., Wang X., Zhou W., Ye L., Li J.L., Wang Y.Z., Ho W.Z. (2012) IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT Pathway. PLoS One 7: e35902.
40. Wang Y., Wang X., Ye L., Li J., Song L., Fulambarkar N., Ho W. (2012) Morphine suppresses IFN signaling pathway and enhances AIDS virus infection. PLoS One 7: e31167.
41. Geiben-Lynn R. (2002) Anti-human immunodeficiency virus noncytolytic CD8+ T-cell response: a review. AIDS Patient Care STDS 16: 471-7.
42. Maciaszek J.W., Parada N.A., Cruikshank W.W., Center D.M., Kornfeld H., Viglianti G.A. (1997) IL-16 represses HIV-1 promoter activity. J Immunol 158: 5-8.
43. Zhou P., Goldstein S., Devadas K., Tewari D., Notkins A.L. (1997) Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med 3: 659-64.
44. Pal R., Garzino-Demo A., Markham P.D., Burns J., Brown M., Gallo R.C., Devico A.L. (1997) Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278: 695-8.
45. Patterson B.K., Behbahani H., Kabat W.J., Sullivan Y., O'gorman M.R., Landay A., Flener Z., Khan N., Yogev R., Andersson J. (2001) Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest 107: 287-94.
46. Bailer R.T., Holloway A., Sun J., Margolick J.B., Martin M., Kostman J., Montaner L.J. (1999) IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. J Immunol 162: 7534-42.
47. Kedzierska K., Crowe S.M. (2001) Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 12: 133-50.
48. Lambert J.S., Machado E.S., Watson D.C., Sill A.M., Lim J.K., Charurat M., Cunha S.M., Afonso A.O., Oliviera R.H., Tanuri A., Devico A.L. (2007) Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children. Pediatr Infect Dis J 26: 935-44.
49. Mcneely T.B., Shugars D.C., Rosendahl M., Tucker C., Eisenberg S.P., Wahl S.M. (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-9.
50. Pillay K., Coutsoudis A., Agadzi-Naqvi A.K., Kuhn L., Coovadia H.M., Janoff E.N. (2001) Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 183: 653-6.
51. Tseng C.C., Tseng C.P. (2000) Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement. FEBS Lett 475: 232-6.
52. Py B., Basmaciogullari S., Bouchet J., Zarka M., Moura I.C., Benhamou M., Monteiro R.C., Hocini H., Madrid R., Benichou S. (2009) The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One 4: e5006.
53. Ma G., Greenwell-Wild T., Lei K., Jin W., Swisher J., Hardegen N., Wild C.T., Wahl S.M. (2004) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 200: 1337-46.
54. Iqbal S.M., Ball T.B., Levinson P., Maranan L., Jaoko W., Wachihi C., Pak B.J., Podust V.N., Broliden K., Hirbod T., Kaul R., Plummer F.A. (2009) Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 23: 1669-77.
55. Ghosh M., Fahey J.V., Shen Z., Lahey T., Cu-Uvin S., Wu Z., Mayer K., Wright P.F., Kappes J.C., Ochsenbauer C., Wira C.R. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5: e11366.
56. Ghosh M., Shen Z., Fahey J.V., Cu-Uvin S., Mayer K., Wira C.R. (2010) Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 129: 207-19.
57. Machmach K., Leal M., Gras C., Viciana P., Genebat M., Franco E., Boufassa F., Lambotte O., Herbeuval J.P., Ruiz-Mateos E. (2012) Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol 86: 4245-52.
58. Chehimi J., Campbell D.E., Azzoni L., Bacheller D., Papasavvas E., Jerandi G., Mounzer K., Kostman J., Trinchieri G., Montaner L.J. (2002) Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 168: 4796-801.
59. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., Salazar A.M., Colonna M., Steinman R.M. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-602.
60. Brinkmann V., Geiger T., Alkan S., Heusser C.H. (1993) Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 178: 1655-63.
61. Michaelis B., Levy J.A. (1989) HIV replication can be blocked by recombinant human interferon beta. AIDS 3: 27-31.
62. Emilie D., Burgard M., Lascoux-Combe C., Laughlin M., Krzysiek R., Pignon C., Rudent A., Molina J.M., Livrozet J.M., Souala F., Chene G., Grangeot-Keros L., Galanaud P., Sereni D., Rouzioux C. (2001) Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 15: 1435-7.
63. Kamga I., Kahi S., Develioglu L., Lichtner M., Maranon C., Deveau C., Meyer L., Goujard C., Lebon P., Sinet M., Hosmalin A. (2005) Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 192: 303-10.
64. Boasso A., Herbeuval J.-P., Hardy A.W., Anderson S.A., Dolan M.J., Fuchs D., Shearer G.M. (2007) HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 109: 3351-9.
65. Manches O., Munn D., Fallahi A., Lifson J., Chaperot L., Plumas J., Bhardwaj N. (2008) HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2, 3-dioxygenase-dependent mechanism. J Clin Invest 118: 3431-9.
66. Boasso A., Shearer G.M. (2008) Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 126: 235-42.
67. Boasso A., Hardy A.W., Anderson S.A., Dolan M.J., Shearer G.M. (2008) HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 3: e2961.
68. Herbeuval J.-P., Shearer G.M. (2007) HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 123: 121-8.
69. Herbeuval J.-P., Nilsson J., Boasso A., Hardy A.W., Kruhlak M.J., Anderson S.A., Dolan M.J., Dy M., Andersson J., Shearer G.M. (2006) Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A 103: 7000-5.
70. Shankar E.M., Che K.F., Messmer D., Lifson J.D., Larsson M. (2011) Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells. Mol Med 17: 229-40.
71. Che K.F., Sabado R.L., Shankar E. M., Tjomsland V., Messmer D., Bhardwaj N., Lifson J.D., Larsson M. (2010) HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells. Eur J Immunol 40(8):2248-58.
72. Boasso A., Shearer G.M. (2007) How does indoleamine 2, 3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab 8: 217-23.
73. Estes J.D., Li Q., Reynolds M.R., Wietgrefe S., Duan L., Schacker T., Picker L.J., Watkins D.I., Lifson J.D., Reilly C., Carlis J., Haase A.T. (2006) Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 193: 703-12.
74. Mellor A.L., Munn D.H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-74.
75. Fallarino F., Gizzi S., Mosci P., Grohmann U., Puccetti P. (2007) Tryptophan catabolism in IDO +plasmacytoid dendritic cells. Curr Drug Metab 8: 209-16.
76. Kawaguchi R., Shimokawa T., Umehara N., Nunomura S., Tanaka T., Ra C. (2008) Priming of peripheral monocytes with prolactin (PRL) sensitizes IFN-gamma-mediated indoleamine 2, 3-dioxygenase (IDO) expression without affecting IFN-gamma signaling. J Reprod Immunol 77: 117-25.
77. Mellor A.L., Munn D.H. (2003) Tryptophan catabolism and regulation of adaptive immunity. J Immunol 170: 5809-13.
78. Potula R., Poluektova L., Knipe B., Chrastil J., Heilman D., Dou H., Takikawa O., Munn D.H., Gendelman H.E., Persidsky Y. (2005) Inhibition of indoleamine 2, 3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 106: 2382-90.
79. Ma J., Li X., Xu J., Zhang Q., Liu Z., Jia P., Zhou J., Guo F., You X., Yu L., Zhao L., Jiang J., Cen S. (2011) Retraction: the cellular source for APOBEC3G's incorporation into HIV-1. Retrovirology 8: 88.
80. Monajemi M., Woodworth C.F., Benkaroun J., Grant M., Larijani M. (2012) Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology 9: 35.
81. Asaoka K., Ikeda K., Hishinuma T., Horie-Inoue K., Takeda S., Inoue S. (2005) A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun 338: 1950-6.
82. Chen K., Huang J., Zhang C., Huang S., Nunnari G., Wang F.-X., Tong X., Gao L., Nikisher K., Zhang H. (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 80: 7645-57.
83. Peng G., Lei K.J., Jin W., Greenwell-Wild T., Wahl S.M. (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 203: 41-6.
84. Wang Y., Bergmeier L.A., Stebbings R., Seidl T., Whittall T., Singh M., Berry N., Almond N., Lehner T. (2009) Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 27: 870-81.
85. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. (2007) An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2: 193-203.
86. Goffinet C., Allespach I., Homann S., Tervo H.-M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Krausslich H.-G., Fackler O.T., Keppler O.T. (2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5: 285-97.
87. Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B., Wang Y.-H., Shaw J.L., Du Q., Li C., Arai N., Yao Z., Lanier L.L., Liu Y.-J. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206: 1603-14.
88. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., Evans D.T. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5: e1000429.
89. Zhang F., Wilson S.J., Landford W.C., Virgen B., Gregory D., Johnson M.C., Munch J., Kirchhoff F., Bieniasz P.D., Hatziioannou T. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54-67.
90. Saphire A.C., Bobardt M.D., Gallay P.A. (2000) Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells. Immunol Res 21: 211-7.
91. Daelemans D., Dumont J.-M., Rosenwirth B., De Clercq E., Pannecouque C. (2010) Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral Res 85: 418-21.
92. Yan N., Regalado-Magdos A.D., Stiggelbout B., Lee-Kirsch M.A., Lieberman J. (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11: 1005-13.
93. Shi J., Zhou J., Shah V.B., Aiken C., Whitby K. (2011) Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85: 542-9.
94. Schaller T., Goujon C., Malim MH. (2012) AIDS/HIV. HIV interplay with SAMHD1. Science 335: 1313-4.
95. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., Schulte R., Gissmann L., Muller M., Sacher A., Racz P., Steinman R.M., Uguccioni M., Ignatius R. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5: e1000373.
96. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., Schlesinger S.J., Colonna M., Steinman R.M. (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105: 2574-9.
97. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.-S., Reis E Sousa C., Matsuura Y., Fujita T., Akira S. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-5.
98. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-8.
99. Castelli J., Thomas E.K., Gilliet M., Liu Y.J., Levy J.A. (2004) Mature dendritic cells can enhance CD8+ cell noncytotoxic anti-HIV responses: the role of IL-15. Blood 103: 2699-704.
100. D'ettorre G., Forcina G., Lichtner M., Mengoni F., D'agostino C., Massetti A.P., Mastroianni C.M., Vullo V. (2002) Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. AIDS 16: 181-8.
101. Chernoff A.E., Granowitz E.V., Shapiro L., Vannier E., Lonnemann G., Angel J.B., Kennedy J.S., Rabson A.R., Wolff S.M., Dinarello C.A. (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492-9.
102. Ansari A.A., Mayne A.E., Sundstrom J.B., Bostik P., Grimm B., Altman J.D., Villinger F. (2002) Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J Virol 76: 1731-43.
103. Ahlers J.D., Belyakov I.M., Matsui S., Berzofsky J.A. (2001) Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol 13: 897-908.
104. Steinstraesser L., Tippler B., Mertens J., Lamme E., Homann H.H., Lehnhardt M., Wildner O., Steinau H.U., Uberla K. (2005) Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2: 2.